🔎 Trials Near Me

Akèy › Obèsite › Pennsylvania

Etid klinik pou Obèsite nan Pennsylvania

49 etid pou Obèsite ap chèche patisipan nan sit nan Pennsylvania.

Vil nan Pennsylvania

Tèks ofisyèl etid la (Anglè)

A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event

  • Suburban Research Associates, West Chester
  • Cardiology Consultants of Philadelphia Yardley, Yardley
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT07783802

A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight

  • UPMC Child Hosp-Pittsburgh, Pittsburgh
Ap rekriteFaz 3
Laj 8 a 18 · Tout sèks · Mizajou Sep 30, 2026 · NCT07253285

A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight

  • Heritage Valley Medical Group, Beaver
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT07564414

A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide

  • Geisinger Clinic, Danville
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT07668414

A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)

  • UPMC Children's Hospital of Pittsburgh, Pittsburgh
Ap rekriteFaz 3
Laj 6 a 17 · Tout sèks · Mizajou Sep 24, 2026 · NCT06672549

AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose Weight

  • UPA Ctr Weight and Eating Dis, Philadelphia
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2026 · NCT07339423

Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study

  • Thomas Jefferson University - Medicine/GI and Hepatology, Philadelphia
Ap rekriteFaz 3
Laj 18 a 70 · Tout sèks · Mizajou Sep 24, 2026 · NCT06937086

Cardiovascular Effects of Angiotensin-(1-7) in Obesity Hypertension

  • Penn State Milton S. Hershey Medical Center, Hershey
Ap rekriteFaz 1 bonè
Laj 18 a 65 · Tout sèks · Mizajou Sep 24, 2026 · NCT06482853

Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

  • Thomas Jefferson University - Medicine/GI and Hepatology, Philadelphia
Ap rekriteFaz 3
Laj 18 a 70 · Tout sèks · Mizajou Sep 24, 2026 · NCT06937099

A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee

  • University Orthopedics Center, Altoona
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07153471

A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes

  • Preferred Primary Care Physicians, Preferred Clinical Research-St. Clair, Pittsburgh
  • Preferred Primary Care Physicians, Uniontown
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07282600

Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

  • Heritage Valley Multispecialty Group Inc, Beaver
  • Capital Area Research LLC, Camp Hill
  • Abington Medical Specialists, Horsham
Ap rekriteFaz 3
Laj 45 a 99 · Tout sèks · Mizajou Sep 22, 2026 · NCT07037433

Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight

  • Keystone Clinical Studies, Plymouth Meeting
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07353931

A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes

  • Preferred Primary Care Physicians, Uniontown
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07321886

A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight

  • Research Site, Scottdale
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07784270

A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin

  • Preferred Primary Care Physicians, Preferred Clinical Research (Ofc 18), Pittsburgh
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07392190

Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

  • Abington Medical Specialists, Horsham
  • University of Pittsburgh Medical Center, Pittsburgh
Ap rekriteFaz 3
Laj 18 a 99 · Tout sèks · Mizajou Sep 16, 2026 · NCT07037459

A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes

  • AURORA-2 Clinical Site, Philadelphia
  • AURORA-2 Clinical Site, Pittsburgh
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 16, 2026 · NCT07743450

A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

  • AURORA-1 Clinical Site, Philadelphia
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 16, 2026 · NCT07743463

A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes

  • VA Pittsburgh Healthcare System, Pittsburgh
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 14, 2026 · NCT07351058

A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes

  • Suburban Research Associates - West Chester Office, West Chester
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 14, 2026 · NCT07351045

A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide

  • Frontier Clinical Research, LLC, Scottdale
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Sep 14, 2026 · NCT06897475

A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)

  • ACCOMPLISH-2 Research Site, Philadelphia
Ap rekriteFaz 3Volontè an sante akeyi
Laj 18 a 79 · Tout sèks · Mizajou Sep 11, 2026 · NCT07654374

Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight

  • UPA Ctr Weight and Eating Dis, Philadelphia
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 9, 2026 · NCT07770841

Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)

  • Capital Area Research LLC, Newport
Ap rekriteFaz 3
Laj 18 a 99 · Tout sèks · Mizajou Sep 3, 2026 · NCT07684235

Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)

  • Altoona Center for Clinical Research, Duncansville
Ap rekriteFaz 3
Laj 18 a 99 · Tout sèks · Mizajou Aug 27, 2026 · NCT07575399

A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus

  • Research Site, Philadelphia
  • Research Site, Smithfield
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Aug 25, 2026 · NCT07784725

Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL

  • Children's Hospital of Philadelphia, Philadelphia
Ap rekriteFaz 2
Laj 7 a 25 · Tout sèks · Mizajou Aug 19, 2026 · NCT05082519

A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity

  • Penn State Hlth Holy Spirit Med Ctr, Camp Hill
  • Chambersburg Hospital, Chambersburg
  • Doylestown Heath cardiology, Doylestown
  • ak 2 plis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Aug 18, 2026 · NCT07567001

Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)

  • ACCOMPLISH-1 Research Site, Philadelphia
Ap rekriteFaz 3
Laj 18 a 79 · Tout sèks · Mizajou Aug 10, 2026 · NCT07654361

Pharmacogenetics of Response to GLP1R Agonists

  • Amish Research Clinic, Lancaster
Ap rekriteFaz 1Volontè an sante akeyi
Laj 18 a 89 · Tout sèks · Mizajou Jul 27, 2026 · NCT05071898

A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia

  • Altoona Center for Clinical Research, Duncansville
Ap rekriteFaz 2
Laj 18 a 80 · Tout sèks · Mizajou Jul 22, 2026 · NCT07477704

An Acceptance-Based Healthy Lifestyle Intervention for Diverse Adolescents

  • Drexel University, Philadelphia
Ap rekriteVolontè an sante akeyi
Laj 14 a 19 · Fanm · Mizajou Jul 20, 2026 · NCT06147973

Weight Bias Reducation Intervention With Nursing Students Using Simulation: The BRAVE Study

  • Villanova University, Villanova
Ap rekrite
Laj 18 a 35 · Tout sèks · Mizajou Jul 17, 2026 · NCT07334470

Intensive Glycemic Targets in Overweight and Obese Women With Gestational Diabetes

  • University of Pittsburgh, Pittsburgh
Ap rekrite
Laj 18 a 45 · Fanm · Mizajou Jun 24, 2026 · NCT05124808

Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.